Artificial Pancreas Device Market is expected to rise at a CAGR of 16.33% by 2032, estimates DelveInsight

The global artificial pancreas device market was valued at USD 334.76 million in 2024 and is projected to expand at a CAGR of 16.33% from 2025 to 2032, reaching USD 1,116.86 million by 2032. The growing prevalence of diabetes worldwide remains the primary factor driving market growth, as the rising patient base fuels demand for advanced diabetes management solutions. Increased awareness and widespread screening initiatives have facilitated earlier diagnosis and improved disease management, further accelerating the adoption of artificial pancreas systems. In addition, continuous product innovation and development by leading industry players have led to more efficient and accessible devices, enhancing treatment outcomes. Together, these factors are anticipated to propel the artificial pancreas device market throughout the forecast period from 2025 to 2032.

DelveInsight's Artificial Pancreas Device Market Insights report provides the current and forecast market analysis, individual leading Artificial Pancreas Device companies' market shares, challenges, Artificial Pancreas Device market drivers, barriers, and trends, and key Artificial Pancreas Device companies in the market.

Request for a sample page report @ https://www.delveinsight.com/report-store/artificial-pancreas-device-system-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key Takeaways from the Artificial Pancreas Device Market Report
The Artificial Pancreas Device market is projected to grow at a moderate CAGR from 2025 to 2032.
As per DelveInsight estimates, North America is anticipated to dominate the global Artificial Pancreas Device market during the forecast period.
Notable Artificial Pancreas Device companies such as Medtronic PLC, Insulet Corporation, Tandem Diabetes Care, Inc., Beta Bionics, Inc., BIGFOOT BIOMEDICAL, INC., CamDiab Ltd., Diabeloop SA, Ypsomed, INREDA® DIABETIC B.V., Nikkiso Co., Ltd., Pancreum, Inc., Johnson & Johnson Services, Inc., Dexcom, Inc., TypeZero Technologies, Animas Corporation, and several others are currently operating in the Artificial Pancreas Device market.
In September 2024, Tandem Diabetes Care, Inc. announced that its t:slim X2 insulin pump, integrated with Control-IQ automated insulin delivery (AID) technology, received clearance in the European Union (EU) for use with Eli Lilly and Company's Lyumjev® (insulin lispro-aabc injection), an ultra-rapid-acting insulin.
Similarly, in June 2024, MCRA-a prominent independent Clinical Research Organization (CRO) specializing in medical devices, diagnostics, and biologics-revealed its contribution in supporting CamDiab's artificial pancreas software, CamAPS FX, in securing clearance from the U.S. Food and Drug Administration (FDA).

To read more about the latest highlights related to the Artificial Pancreas Device market, get a snapshot of the key highlights entailed in the Global Artificial Pancreas Device Market Report https://www.delveinsight.com/sample-request/artificial-pancreas-device-system-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr


Artificial Pancreas Device Overview

Artificial pancreas devices are advanced systems designed to automate blood glucose management in individuals with diabetes, particularly type 1 diabetes. These systems integrate three core components: a continuous glucose monitor (CGM), an insulin pump, and a computer-controlled algorithm. Together, they mimic the function of a healthy pancreas by continuously monitoring glucose levels and automatically adjusting insulin delivery in real time.

The primary goal of artificial pancreas technology is to maintain optimal blood glucose control, reduce the risk of both hyperglycemia and hypoglycemia, and ease the burden of daily diabetes management. Compared to traditional insulin therapy methods such as multiple daily injections, artificial pancreas systems significantly improve patient outcomes, quality of life, and adherence to treatment.

The devices are especially valuable for children, adolescents, and adults with type 1 diabetes, as well as pregnant women experiencing gestational diabetes. Ongoing advancements in closed-loop systems, interoperability with various insulin types, and user-friendly smartphone integration are driving their adoption worldwide.

With rising global diabetes prevalence, increasing awareness of advanced diabetes care, and supportive regulatory approvals, artificial pancreas devices represent a transformative innovation in diabetes management, poised to see strong growth in the coming years.

Artificial Pancreas Device Market Insights

North America is projected to dominate the artificial pancreas device market in 2024, holding the largest share among all regions. This growth is primarily driven by the increasing prevalence of diabetes, strong government healthcare initiatives, the presence of leading market players engaged in strategic product development, and rising public awareness about advanced diabetes management.

According to the Centers for Disease Control and Prevention (CDC, 2024), approximately 38.4 million people of all ages-representing 11.6% of the U.S. population-were living with diabetes. Among them, 38.1 million adults aged 18 years and older, or 14.7% of U.S. adults, were affected in 2021. The growing diabetes burden, particularly type 1 diabetes, highlights the demand for innovative technologies that simplify blood glucose management. Artificial pancreas systems, which automate insulin delivery while continuously monitoring glucose levels, provide an effective solution to improve patient outcomes and ease the challenges of daily management, thereby fueling market growth in the region.

Awareness programs also play a key role in market expansion. For instance, initiatives by the National Institutes of Health (NIH) and the CDC, through the National Diabetes Education Program (NDEP), focus on educating communities about the benefits of continuous glucose monitoring and automated insulin delivery systems, including artificial pancreas devices.

Moreover, strategic advancements by industry players are further strengthening the regional market. A notable example occurred in May 2024, when the U.S. Food and Drug Administration (FDA) approved the CamAPS FX artificial pancreas, developed by the University of Cambridge, for individuals with type 1 diabetes aged two years and older, including use during pregnancy.

To know more about why North America is leading the market growth in the Artificial Pancreas Device market, get a snapshot of the Artificial Pancreas Device Market Outlook https://www.delveinsight.com/report-store/artificial-pancreas-device-system-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr


Artificial Pancreas Device Market Dynamics

According to the latest update from the International Diabetes Federation (IDF), around 537 million adults aged 20-79 were living with diabetes worldwide in 2021. This figure is expected to rise to 643 million by 2030 and further to 783 million by 2045.

The IDF Diabetes Atlas (2022) reported that out of 8.75 million people globally with type 1 diabetes, 1.52 million were under the age of 20. Interestingly, 62% of all new type 1 diabetes diagnoses in 2022 occurred in individuals aged 20 years or older. As diabetes requires lifelong monitoring and precise insulin regulation, artificial pancreas systems-which integrate insulin pumps with continuous glucose monitoring (CGM) to enable automated insulin delivery-represent a major advancement in improving quality of life for patients.

Hyperglycemia during pregnancy also remains a significant concern, posing health risks to both mothers and infants, including preterm birth, macrosomia, and preeclampsia. According to the IDF (2025), about 21.1 million live births globally (16.7%) were impacted by hyperglycemia in pregnancy. Women over 45 and those with a history of gestational diabetes face a higher likelihood of developing type 2 diabetes after delivery. Maintaining stable blood glucose levels is therefore essential for safe pregnancies. However, conventional management methods, such as multiple daily insulin injections, can be difficult due to hormonal fluctuations that trigger unpredictable glucose levels. Artificial pancreas devices, by automating insulin delivery through CGM-based monitoring, offer an efficient solution to stabilize glucose levels with minimal manual intervention-driving global adoption and market growth.

Artificial Pancreas Device Market Drivers:
Rising cases of diabetes
Rising awareness and screening programs
Increase in product development activities across the globe

Get a sneak peek at the Artificial Pancreas Device market dynamics @ https://www.delveinsight.com/sample-request/artificial-pancreas-device-system-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr


Scope of the Artificial Pancreas Device Market Report:
Coverage: Global
Study Period: 2022 to 2032
Key Artificial Pancreas Device Companies: Medtronic PLC, Insulet Corporation, Tandem Diabetes Care, Inc., Beta Bionics, Inc., BIGFOOT BIOMEDICAL, INC., CamDiab Ltd., Diabeloop SA, Ypsomed, INREDA® DIABETIC B.V., Nikkiso Co., Ltd., Pancreum, Inc., Johnson & Johnson Services, Inc., Dexcom, Inc., TypeZero Technologies, Animas Corporation, and others.

Which MedTech key players in the Artificial Pancreas Device market are set to emerge as the trendsetter, explore @ Artificial Pancreas Device Companies https://www.delveinsight.com/report-store/artificial-pancreas-device-system-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Trending Reports By DelveInsight:

Functional Constipation Market
https://www.delveinsight.com/report-store/chronic-constipation-market

Leber's Hereditary Optic Neuropathy Market
https://www.delveinsight.com/report-store/lebers-hereditary-optic-neuropathy-lhon-market

Gastric Neuroendocrine Tumors Market
https://www.delveinsight.com/report-store/gastric-neuroendocrine-tumors-market

Immune Thrombocytopenic Purpura Market
https://www.delveinsight.com/report-store/immune-thrombocytopenia-itp-market

Visceral Pain Associated With GI Disorders Market
https://www.delveinsight.com/report-store/visceral-pain-associated-with-gi-disorders-market

Bullous Pemphigoid Market
https://www.delveinsight.com/report-store/bullous-pemphigoid-market

Cyclin-dependent Kinase-like 5 Deficiency Disorder Market https://www.delveinsight.com/infographics/cyclin-dependent-kinase-like-5-cdkl5-deficiency-disorder-market

Myocarditis Market
https://www.delveinsight.com/report-store/myocarditis-market

Recurrent Blood Clots Market
https://www.delveinsight.com/report-store/recurrent-blood-clots-thrombophilia-market

Zollinger-ellison Syndrome Market
https://www.delveinsight.com/report-store/zollinger-ellison-syndrome-market

Age-related Hearing Loss Medical Device Market
https://www.delveinsight.com/blog/age-related-hearing-loss-device-market

Heart Sounds Sensors Market
https://www.delveinsight.com/report-store/heart-sounds-sensors-electronic-stethoscope-market

Hypoplastic Left Heart Syndrome Market
https://www.delveinsight.com/report-store/hypoplastic-left-heart-syndrome-market

Infectious Arthritis/Septic Arthritis Market
https://www.delveinsight.com/report-store/infectious-arthritisseptic-arthritis-market

Plasmacytoma Market
https://www.delveinsight.com/report-store/plasmacytoma-market

Agoraphobia Market
https://www.delveinsight.com/report-store/agoraphobia-market

Clinically Isolated Syndrome Market
https://www.delveinsight.com/report-store/clinically-isolated-syndrome-cis-market

Fucosidosis Market
https://www.delveinsight.com/report-store/fucosidosis-market

Major Depressive Disorder Market
https://www.delveinsight.com/report-store/major-depressive-disorder-market

Neuronal Ceroid-lipofuscinoses Market
https://www.delveinsight.com/report-store/neuronal-ceroid-lipofuscinoses-cln1-disease-market

Orthotic Devices Market
https://www.delveinsight.com/report-store/orthotic-devices-market

Contact Info:

Kritika Rehani
Assistant Manager, Digital Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a premier healthcare business consultant and market research firm, specializing in life sciences. We empower pharmaceutical companies with comprehensive end-to-end solutions designed to enhance performance and drive growth.

Our expert healthcare consulting services offer in-depth market analysis, helping businesses accelerate growth and navigate challenges with actionable, results-driven strategies.

This release was published on openPR.